AVTXAvalo Therapeutics, Inc.
$13.43-0.37% 1Y
$13.43
$12.7452 weeks$22.87
Price
-0.37%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, a flag to check, the market undecided.
P/En/a
Market value$706.0M
1 year-0.37%
5 years-100%
Charts
As reported to the SEC, without any scoring.
For the full year FY2025, revenue was $59K (−87% year on year) and net income −$78M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates.Earnings release · press release
- Jun 23, 2026On June 23, 2026, the board of directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Ron Philip to the Board, effective June 23, 2026.Director or officer change · Form 8-K
- Jun 16, 2026On June 16, 2026, Avalo Therapeutics, Inc. (the “Company”) issued a press release announcing the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody (mAb) with the potential for development in hidradenitis suppurativa (HS) as well as additional inflammatory disorders.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.